16.31

0.12% -0.02

Anika Therapeutics Inc (ANIK)

Overview News Price History Option Chain Financials Discussions Forecast

Anika Therapeutics Inc stock is traded at $16.31, with a volume of 205.91K. It is down -0.12% in the last 24 hours and down -5.06% over the past month. Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.

Previous Close:

$16.33

Open:

$16.15

24h Volume:

205.91K

Relative Volume:

2.21

Market Cap:

$238.87M

Revenue:

$166.88M

Net Income/Loss:

$-74.18M

P/E Ratio:

-10.66

EPS:

-1.53

Net Cash Flow:

$1.14M

1W Performance:

-4.95%

1M Performance:

-5.06%

6M Performance:

-37.22%

1Y Performance:

-26.76%

1-Day Range:

$15.96

$17.04

1-Week Range:

$15.82

$17.30

52-Week Range:

$15.82

$29.11

Anika Therapeutics Inc Stock (ANIK) Company Profile

Name

Anika Therapeutics Inc

Sector

Healthcare (1176)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

(781) 457-9000

Address

32 WIGGINS AVENUE, BEDFORD, MA

Employee

357

Twitter

Next Earnings Date

2024-10-31

Latest SEC Filings

ANIK's Discussions on Twitter

Compare ANIK with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ANIK Anika Therapeutics Inc	16.31	238.87M	166.88M	-74.18M	1.14M	-5.07
ZTS Zoetis Inc	164.84	74.37B	9.15B	2.43B	2.31B	5.32
HLN Haleon Plc Adr	9.69	43.81B	14.26B	1.55B	0	0.3383
TAK Takeda Pharmaceutical Co Adr	13.10	41.53B	30.27B	1.93B	3.45B	0.6044
TEVA Teva Pharmaceutical Industries Ltd Adr	22.09	25.03B	16.77B	-959.00M	1.37B	-0.85
VTRS Viatris Inc	12.52	14.94B	15.05B	-883.30M	1.89B	-0.74

Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-01-24	Reiterated	Barrington Research	Outperform
Aug-14-23	Upgrade	Barrington Research	Mkt Perform → Outperform
Mar-07-23	Downgrade	Barrington Research	Outperform → Mkt Perform
Nov-09-22	Upgrade	Barrington Research	Mkt Perform → Outperform
Oct-14-22	Resumed	Stephens	Equal-Weight
Mar-09-22	Downgrade	Barrington Research	Outperform → Mkt Perform
Mar-09-22	Downgrade	Stephens	Overweight → Equal-Weight
Nov-16-21	Initiated	Stephens	Overweight
Jul-16-21	Initiated	UBS	Neutral
Dec-16-20	Upgrade	Barrington Research	Mkt Perform → Outperform
May-08-20	Downgrade	Barrington Research	Outperform → Mkt Perform
Jan-21-20	Upgrade	Sidoti	Neutral → Buy
Jan-10-20	Upgrade	First Analysis Sec	Outperform → Strong Buy
Nov-05-19	Initiated	BWS Financial	Sell
Sep-24-19	Reiterated	Barrington Research	Outperform
Sep-23-19	Downgrade	First Analysis Sec	Strong Buy → Outperform
Jul-25-19	Upgrade	First Analysis Sec	Neutral → Strong Buy
Feb-22-19	Downgrade	First Analysis Sec	Outperform → Neutral
Feb-22-19	Downgrade	Sidoti	Buy → Neutral
Jul-27-18	Upgrade	Barrington Research	Mkt Perform → Outperform
Jun-20-18	Downgrade	Barrington Research	Outperform → Mkt Perform
Jun-20-18	Downgrade	First Analysis Sec	Overweight → Equal-Weight
May-04-18	Upgrade	Barrington Research	Mkt Perform → Outperform
Feb-23-18	Downgrade	Barrington Research	Outperform → Mkt Perform
Jan-24-18	Upgrade	First Analysis Sec	Equal-Weight → Overweight
Oct-27-17	Reiterated	Barrington Research	Outperform
May-09-16	Upgrade	Singular Research	BUY - Long-Term → Buy
Apr-27-16	Downgrade	Northland Capital	Outperform → Market Perform
Feb-26-16	Reiterated	Barrington Research	Outperform

View All

Anika Therapeutics Inc Stock (ANIK) Latest News

Dec 19, 2024

Fmr LLC Acquires 4,996 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World

Dec 19, 2024

Improved Revenues Required Before Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Find Their Feet - Simply Wall St

Dec 19, 2024

Dec 18, 2024

ANIK (Anika Therapeutics) Net Issuance of Preferred Stock : $0.0 Mil (TTM As of Sep. 2024) - GuruFocus.com

Nov 28, 2024

Nov 26, 2024

Osteoarthritis Therapeutics Market Size to Reach USD 24.34 Bn by 2034 - GlobeNewswire Inc.

Nov 26, 2024

Nov 22, 2024

Anika Therapeutics to Present at Three Major Healthcare Investor Conferences in December | ANIK Stock News - StockTitan

Nov 22, 2024

Anika To Participate in December 2024 Investor Conferences - GlobeNewswire

Nov 22, 2024

Nov 20, 2024

Orthopedic Regenerative Surgical Products Market to Witness - openPR

Nov 20, 2024

Nov 19, 2024

Joint Pain Injection Market Size, Share, Trends, - openPR

Nov 19, 2024

Nov 11, 2024

New Strong Sell Stocks for November 11th - Yahoo Canada Finance

Nov 11, 2024

Nov 08, 2024

Orthobiologics Market Size, Growth, Opportunities 2024-2032 | - openPR

Nov 08, 2024

Nov 06, 2024

Anika Therapeutics Navigates Geopolitical Risks Amid Global Conflicts - TipRanks

Nov 06, 2024

Nov 05, 2024

Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Sold by Capital Management Corp VA - MarketBeat

Nov 05, 2024

Anika Therapeutics Announces Third Quarter Financial ResultsOn October 31, 2024, Anika Therapeutics, Inc. released a press statement unveiling its financial outcomes for the third quarter concluding on September 30, 2024. As per the report - Defense World

Nov 05, 2024

Viscosupplementation Market Report Analysis, Growth - openPR

Nov 05, 2024

Nov 04, 2024

Anika Therapeutics (NASDAQ:ANIK) Downgraded to Hold Rating by StockNews.com - MarketBeat

Nov 04, 2024

Anika Therapeutics, Inc. (NASDAQ:ANIK) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 04, 2024

Barrington Research Cuts Anika Therapeutics (NASDAQ:ANIK) Price Target to $25.00 - Defense World

Nov 04, 2024

Nov 03, 2024

Earnings call: Anika Therapeutics Focuses on HA Products Amid Restructuring By Investing.com - Investing.com South Africa

Nov 03, 2024

Earnings call: Anika Therapeutics Focuses on HA Products Amid Restructuring - Investing.com

Nov 03, 2024

Nov 02, 2024

Anika Therapeutics Third Quarter 2024 Earnings: Misses Expectations - Simply Wall St

Nov 02, 2024

Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 02, 2024

Nov 01, 2024

Anika Therapeutics (NASDAQ:ANIK) Given New $25.00 Price Target at Barrington Research - MarketBeat

Nov 01, 2024

Anika Therapeutics (NASDAQ:ANIK shareholders incur further losses as stock declines 30% this week, taking five-year losses to 72% - Simply Wall St

Nov 01, 2024

Anika: Q3 Earnings Snapshot - New Haven Register

Nov 01, 2024